BioCryst Pharmaceuticals
(NASDAQ) BCRX
BioCryst Pharmaceuticals Financials at a Glance
Market Cap
$2.53B
Revenue (TTM)
$885.72M
Net Income (TTM)
-$457.98M
EPS (TTM)
-$1.78
P/E Ratio
-5.60
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Price
$9.62
Volume
145,495
Open
$9.94
Price
$9.62
Volume
145,495
Open
$9.94
Previous Close
$9.94
Daily Range
$9.48 - $10.04
52-Week Range
$6.00 - $10.94
Estimated Earnings Date
Aug 3, 2026
Dividend
$0.00
Beta (Volatility)
1.10 (Average)
Price
$9.62
Volume
145,495
Open
$9.94
Previous Close
$9.94
Daily Range
$9.48 - $10.04
52-Week Range
$6.00 - $10.94
Estimated Earnings Date
Aug 3, 2026
BCRX News
BCRX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout BioCryst Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
435
CEO
Charles K. Gayer, MBA
Website
www.biocryst.comHeadquarters
Durham, NC 27703, US
BCRX Financials
Key Financial Metrics (TTM)
Gross Margin
18.89%
Operating Margin
-43.11%
Net Income Margin
-51.71%
Return on Equity
123.57%
Return on Capital
106.65%
Return on Assets
-98.48%
Earnings Yield
-17.86%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.53B
Shares Outstanding
254.16M
Volume
145.50K
Avg. Volume
4.89M
Financials (TTM)
Gross Profit
$167.34M
Operating Income
-$381.84M
EBITDA
-$373.25M
Operating Cash Flow
$296.83M
Capital Expenditure
-$2.73M
Free Cash Flow
$294.10M
Cash & ST Invst.
$239.25M
Total Debt
$858.08M
BioCryst Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$156.41M
+7.5%
Gross Profit
-$546.73M
-487.8%
Gross Margin
-3.50%
N/A
Market Cap
$2.53B
N/A
Market Cap/Employee
$4.36M
N/A
Employees
580
N/A
Net Income
-$721.81M
-2255762.5%
EBITDA
-$699.97M
-2947.4%
Quarterly Fundamentals
Total Cash
$239.25M
-19.0%
Total Debt
$858.08M
+3.5%
Accounts Receivable
$109.27M
+17.0%
Inventory
$5.99M
-12.9%
Long Term Debt
$814.67M
+2.8%
Short Term Debt
$43.41M
+16.8%
Return on Assets
-98.48%
N/A
Return on Invested Capital
-1.42%
N/A
Free Cash Flow
-$62.54M
-126.1%
Operating Cash Flow
-$62.14M
-125.8%